Overview

The development of accurate and reproducible immune monitoring assays is essential to determine the immune responses in patients receiving novel immune therapies and ultimately transitioning these therapies from the clinical trial phase to standard of care. The goal of the Translational Immunology Section (TIS) is to develop cutting-edge immune monitoring technology that will be made available to all NIAMS investigators.

The Translational Immunology Section supports NIAMS scientists with:

  • Consultative advice and in-depth instructions in a variety of immunologic methods to facilitate their interpretation of immunoassays most relevant to a particular clinical trial or to study a particular patient.
  • State-of-the-art immunoassays such as high parameters, multicolor flow cytometry, Luminex, and NanoString transcriptomic analysis enabling NIAMS clinicians to monitor the immune responses of their patients.
  • Analysis of a reference population to define baseline responses, ensuring quality control checks that will validate the reproducibility of these results.
  • Analysis of the mechanism of action of JAK inhibitors on various immune cell populations.

Contact Us

Ronnie Gladney

Administrative Assistant
10 Center Drive
Building 10, Room 10N311
Bethesda MD 20892

Core Research Facilities

Labs at the NIAMS are supported by the following state-of-the-art facilities and services:

Scientific Publications

Selected Recent Publications

Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.

Garufi C, Maclean M, Gadina M, Spinelli FR
Expert Rev Clin Immunol.
2022 Mar;
18(3).
doi: 10.1080/1744666X.2022.2042254
PMID: 35168456

Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.

Alexander M, Luo Y, Raimondi G, O'Shea JJ, Gadina M
Pharmaceuticals (Basel).
2021 Dec 30;
15(1).
pii: 48. doi: 10.3390/ph15010048
PMID: 35056105

Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver.

Di Censo C, Marotel M, Mattiola I, Müller L, Scarno G, Pietropaolo G, Peruzzi G, Laffranchi M, Mazej J, Hasim MS, Asif S, Russo E, Tomaipitinca L, Stabile H, Lee SH, Vian L, Gadina M, Gismondi A, Shih HY, Mikami Y, Capuano C, Bernardini G, Bonelli M, Sozzani S, Diefenbach A, Ardolino M, Santoni A, Sciumè G
Eur J Immunol.
2021 Nov;
51(11).
doi: 10.1002/eji.202149209
PMID: 34347289

3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine.

Clement CC, D'Alessandro A, Thangaswamy S, Chalmers S, Furtado R, Spada S, Mondanelli G, Ianni F, Gehrke S, Gargaro M, Manni G, Cara LCL, Runge P, Tsai WL, Karaman S, Arasa J, Fernandez-Rodriguez R, Beck A, Macchiarulo A, Gadina M, Halin C, Fallarino F, Skobe M, Veldhoen M, Moretti S, Formenti S, Demaria S, Soni RK, Galarini R, Sardella R, Lauvau G, Putterman C, Alitalo K, Grohmann U, Santambrogio L
Nat Commun.
2021 Jul 21;
12(1).
doi: 10.1038/s41467-021-24785-3
PMID: 34290243

A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?

Liu C, Kieltyka J, Fleischmann R, Gadina M, O'Shea JJ
Arthritis Rheumatol.
2021 Dec;
73(12).
doi: 10.1002/art.41906
PMID: 34180156

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, Wang X, Naqi M, Playford MP, Goel RR, Li X, Biehl AJ, Ochoa-Navas I, Manna Z, Shi Y, Thomas D, Chen J, Biancotto A, Apps R, Cheung F, Kotliarov Y, Babyak AL, Zhou H, Shi R, Stagliano K, Tsai WL, Vian L, Gazaniga N, Giudice V, Lu S, Brooks SR, MacKay M, Gregersen P, Mehta NN, Remaley AT, Diamond B, O'Shea JJ, Gadina M, Kaplan MJ
Nat Commun.
2021 Jun 7;
12(1).
doi: 10.1038/s41467-021-23361-z
PMID: 34099646

JAK1: Number one in the family; number one in inflammation?

Spinelli FR, Colbert RA, Gadina M
Rheumatology (Oxford).
2021 May 5;
60(Suppl 2).
doi: 10.1093/rheumatology/keab024
PMID: 33950229

Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery.

Clement CC, Nanaware PP, Yamazaki T, Negroni MP, Ramesh K, Morozova K, Thangaswamy S, Graves A, Kim HJ, Li TW, Vigano' M, Soni RK, Gadina M, Tse HY, Galluzzi L, Roche PA, Denzin LK, Stern LJ, Santambrogio L
Immunity.
2021 Apr 13;
54(4).
doi: 10.1016/j.immuni.2021.02.019
PMID: 33725478

Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.

Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adeojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, Rider LG, Colbert RA
Ann Rheum Dis.
2021 Mar;
80(3).
doi: 10.1136/annrheumdis-2020-218690
PMID: 32843325

Translating JAKs to Jakinibs.

Gadina M, Chisolm DA, Philips RL, McInness IB, Changelian PS, O'Shea JJ
J Immunol.
2020 Apr 15;
204(8).
doi: 10.4049/jimmunol.1901477
PMID: 32253269

Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease.

Lalaoui N, Boyden SE, Oda H, Wood GM, Stone DL, Chau D, Liu L, Stoffels M, Kratina T, Lawlor KE, Zaal KJM, Hoffmann PM, Etemadi N, Shield-Artin K, Biben C, Tsai WL, Blake MD, Kuehn HS, Yang D, Anderton H, Silke N, Wachsmuth L, Zheng L, Moura NS, Beck DB, Gutierrez-Cruz G, Ombrello AK, Pinto-Patarroyo GP, Kueh AJ, Herold MJ, Hall C, Wang H, Chae JJ, Dmitrieva NI, McKenzie M, Light A, Barham BK, Jones A, Romeo TM, Zhou Q, Aksentijevich I, Mullikin JC, Gross AJ, Shum AK, Hawkins ED, Masters SL, Lenardo MJ, Boehm M, Rosenzweig SD, Pasparakis M, Voss AK, Gadina M, Kastner DL, Silke J
Nature.
2020 Jan;
577(7788).
doi: 10.1038/s41586-019-1828-5
PMID: 31827281

Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.

Simon N, Antignani A, Hewitt SM, Gadina M, Alewine C, FitzGerald D
JCI Insight.
2019 Mar 7;
4(5).
pii: 123281. doi: 10.1172/jci.insight.123281
PMID: 30720466

Key Publications

JAK inhibitors: Ten years after.

Spinelli FR, Meylan F, O'Shea JJ, Gadina M
Eur J Immunol.
2021 Apr 30;
doi: 10.1002/eji.202048922
PMID: 33930196

Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.

Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, Balanda N, Ross DL, Ospina Cardona D, Wu Z, Patel B, Manthiram K, Groarke EM, Gutierrez-Rodrigues F, Hoffmann P, Rosenzweig S, Nakabo S, Dillon LW, Hourigan CS, Tsai WL, Gupta S, Carmona-Rivera C, Asmar AJ, Xu L, Oda H, Goodspeed W, Barron KS, Nehrebecky M, Jones A, Laird RS, Deuitch N, Rowczenio D, Rominger E, Wells KV, Lee CR, Wang W, Trick M, Mullikin J, Wigerblad G, Brooks S, Dell'Orso S, Deng Z, Chae JJ, Dulau-Florea A, Malicdan MCV, Novacic D, Colbert RA, Kaplan MJ, Gadina M, Savic S, Lachmann HJ, Abu-Asab M, Solomon BD, Retterer K, Gahl WA, Burgess SM, Aksentijevich I, Young NS, Calvo KR, Werner A, Kastner DL, Grayson PC
N Engl J Med.
2020 Dec 31;
383(27).
doi: 10.1056/NEJMoa2026834
PMID: 33108101

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.

Spinelli FR, Conti F, Gadina M
Sci Immunol.
2020 May 8;
5(47).
pii: eabc5367. doi: 10.1126/sciimmunol.abc5367
PMID: 32385052

JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis.

Vian L, Le MT, Gazaniga N, Kieltyka J, Liu C, Pietropaolo G, Dell'Orso S, Brooks SR, Furumoto Y, Thomas CJ, O'Shea JJ, Sciumè G, Gadina M
Front Immunol.
2019;
10().
doi: 10.3389/fimmu.2019.02972
PMID: 31921209

High throughput pSTAT signaling profiling by fluorescent cell barcoding and computational analysis.

Tsai WL, Vian L, Giudice V, Kieltyka J, Liu C, Fonseca V, Gazaniga N, Gao S, Kajigaya S, Young NS, Biancotto A, Gadina M
J Immunol Methods.
2020 Feb;
477().
doi: 10.1016/j.jim.2019.112667
PMID: 31726053

News & Highlights

no-news-results